Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF 270.10
+0.30 (0.11%)
Jun 11, 2025, 3:54 PM CET
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B
Revenue Growth
+3.23%
P/S Ratio
3.47
Revenue / Employee
604.32K
Employees
103,249
Market Cap
216.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 47.05B |
| Lonza Group AG | 6.57B |
| Alcon | 8.77B |
| Galderma Group AG | 4.02B |
| Sandoz Group AG | 9.41B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.87B |
| Ypsomed Holding AG | 748.87M |
Roche Holding AG News
- 1 hour ago - Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH) - Benzinga
- 22 hours ago - Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems - GlobeNewsWire
- 1 day ago - $101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche. - GlobeNewsWire
- 1 day ago - Green Steel Industry Report 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche. - GlobeNewsWire
- 2 days ago - Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy - Benzinga
- 5 days ago - Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients - Reuters
- 7 days ago - Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - Seeking Alpha
- 7 days ago - Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) - GlobeNewsWire